Health
CSOFT’s health blog aims to provide insight into complex diseases, treatment options and regulatory developments, and other prevalent health issues people face today.
FDA Authorizes Pfizer-BioNTech, Moderna COVID Vaccines for Children 6 Months to 4 Years
Friday morning, the U.S. Food and Drug Administration granted Emergency Use Authorization to two COVID-19 vaccines for use in children ages 6 months to 4 years old: one developed by Moderna, and the other developed by Pfizer and BioNTech. The Pfizer vaccine for this...
Galecto Announces First Patient Enrolled in Phase 2 Trial of GB1211 in Combination with Atezolizumab for First-Line Treatment of NSCLCGB1211
Galecto Biotech, Inc., a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced that the first patient has been enrolled in the Phase 2a GALLANT-1 trial (NCT05240131). GALLANT-1 is formulated to study the...
Quoin Pharmaceuticals Announces Licensing and Distribution Agreement with Leading Rare Disease Company for Greater China
Quoin Pharmaceuticals Ltd., a specialty pharmaceutical company focused on rare and orphan diseases, announced it has obtained a license and distribution agreement with Hong Kong WinHealth Pharma Group Ltd. for its lead product candidate, QRX003 for Netherton Syndrome...
Researchers Link Mutations in Long Neglected Non-Coding Genome to Cancer
Researchers from the Dana-Farber Cancer Institute have found a way to examine more closely into a long-neglected, non-coding portion of the human genome, uncovering mechanisms that might drive or suppress cancer development. Since scientists at the Human Genome...
Rune Labs Secures FDA Clearance for Parkinson’s Disease Monitoring through StrivePD Ecosystem on Apple Watch
Rune Labs, a precision neurology company, announced its StrivePD software ecosystem for Parkinson's disease has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) to gather patient symptom data through quantifications made by Apple Watch. By...
GSK Headed to Regulators with RSV Vaccine
The pursuit for an effective vaccine against the respiratory syncytial virus (RSV) may be at an inflection point. GlaxoSmithKline disclosed positive headline data Friday from a pre-specified efficacy interim analysis of the Phase III trial of its RSV vaccine. The...
Degron Therapeutics Launches into Sizzling Hot Protein Degradation Space
Shanghai-based biotechnology company Degron Therapeutics announced that it has secured $22 million in Series A financing for its unique molecular glue-based targeted protein degradation platform GlueXplorer. Degron plans to use the funds generated from this round of...
Vertex Kidney Disease Drug Scores FDA Breakthrough Therapy Designation
Vertex Pharmaceuticals announced on Wednesday that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to its candidate, inaxaplin (VX-147). Inaxaplin was granted the designation for the treatment of APOL1-mediated focal segment...
Seres Touts Strong Phase III Results Against Recurrent C. Difficile Infection
Massachusetts-based Seres Therapeutics, Inc. announced Tuesday that its Phase III Ecospor IV study exhibited a strong safety profile in addition to statistically significant positive results. The study utilizes an open-label design to determine the potential of...
Pear Therapeutics Announces New Analysis Showing Reduction in Healthcare Resource Utilization and Associated Costs in Patients Using reSET® at Six Months
Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), announced a manuscript accepted for publication and available via pre-print of a real-world study displaying reduced...
Categories
ABOUT US
CSOFT Health Sciences has over 15 years of experience providing end-to-end translation and localization solutions for all stages of the product life cycle, from pre-clinical to post-launch. We also specialize in China market access consulting services, Asian regulatory and eCTD submissions. Our operation is compliant with ISO 17100 and certified by BSI in ISO 9001:2015 and ISO 13485:2016, providing customized solutions to meet the rigorous regulatory requirements in global submission. For more information, please visit: www.csoftintl.com